Evidence Amyloid Scan EEG Study

Alzheimer Disease Clinical Trial

— EASES  

Official title:

Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03644043
• Other study ID #: 1R02TCR0072518
• Status: Recruiting
• Start date: July 20, 2018
• Est. completion date: November 30, 2020

Study information

• Verified date: August 2018
• Source: Metabolic Therapy Inc.
• Contact: Dewey Brown II, PhD
• Phone: 2145174004
• Email: kruss3[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Evidence Amyloid Study EEG (EASE) establishes an open-label, longitudinal cohort study to measure of neurological functioning during the onset and progression of cognitive decline in preclinical Alzheimer's patients using quantitative electroencephalography (qEEG) measures (P300, P50, and reaction time). Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi headset with the WAVi EEG P300/P50 system, along with the structured clinical interviews and assessments for baseline screening or mild cognitive impairment which are standard of care.

Description:

Obtain and analyze in-vivo EEG data in participants ages 50-65 showing early onset symptomology of MCI for the purpose of guiding patient management and developing intervention methods for improving overall health outcomes for this segment of the population. Both healthy and symptomatic groups will be populated by participants with previous PET amyloid-beta (Aβ) imaging scans. Incorporate WAVi brain scan technology which has proven effective in assessing cases of mTBI.

Quantitative electroencephalograph (qEEG) is a non-invasive assessment which records multi-channel EEG event-related potentials (ERPs) and a comprehensive multi-dimensional analysis of such recordings by advanced algorithms aimed at understanding and visualizing the network complexity of brain function. Our goal is to compare assessments from both symptomatic and asymptomatic individuals to further develop differential diagnoses in the early-most stages of preclinical AD. Expounding upon an investigative technique that has shown promise in identifying region-specific abnormalities in concussed patients not only allows us to take advantage of an existing framework which provides a clear and elegant topographical output but also establishes a repeatable metric for quantifying MCI related dysfunction. Abiding by the measures within the existing framework contributes to a more standardized neurodiagnostic approach for dementia-related pathologies and supports continuity of care.

Ultimately this neurophysiological assessment will shed new light on the progression of cognitive impairment and the response of developing therapeutic interventions for a variety of neurologic, psychiatric and behavioral conditions. The WAVi system uses algorithms and sets of signal processing and pattern recognition techniques to seek and map activated neural pathways in task-related data points with respect to time, location, amplitude, and frequency. By projecting the individual data points into clusters, they reveal three-dimensional images of brain network activation patterns which represent high resolution functional neural pathways. These brain network patterns and scores can aid clinicians with profiling of brain functionality in comparison to the reference brain network model to assess similarity to normal brain functioning. Measuring alterations in functionality and/or dysfunctionality can potentially assist treatment courses following changes in disease progression. When combined with data supplied from information from self-reported and observed cognitive and behavior patterns clarity arises with respect to brain processes and determination of the medical condition.

For this investigation we will evaluate the ability of qEEG P300 and P50 waveform amplitudes and auditory response times to differentiate healthy aging individuals from those developing MCI characteristics. WAVi recording in the awake-responding state is an ideal low-cost and non-invasive methodology with a high temporal resolution (milliseconds) that provides an optimal investigational tool for the emerging features of brain pathophysiology. These procedures are well-tolerated by patients, unaffected by task difficulty and are widely available to all subpopulations, even those traditionally underrepresented in clinical study. Additionally, they can be repeated over time without habituation effects.

Aim 1 determines individual baseline qEEG P300/P50 amplitudes and auditory response times in a population of healthy participants ages 50-65 without a history of dementia that have previously received PET scan imaging. Assess the population mean, median and variability. If possible, a subset will be retested at a standard interval to determine test-retest reliability for this instrument.

Aim 2 evaluates the ability of qEEG P300 amplitudes and auditory response times to discriminate between aged participants with MCI/preclinical AD symptoms and healthy participants of similar age.

Aim 3 evaluates the ability of qEEG P50 amplitudes to discriminate between aged participants with MCI/preclinical AD symptoms and healthy participants of similar age.

Aim 4 confirms the efficacy of qEEG/amyloid plaque loading correlation with previous PET scan imaging data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: November 30, 2020
• Est. primary completion date: November 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• 65 and older;

• Medicare beneficiary;

• Diagnosis of MCI or dementia, according to DSM-IV and/or National Institutes of Aging-Alzheimer's Association criteria, verified by a dementia specialist within 24 months (American Psychiatric Association. 2000; McKhann et al. 2011; Albert et al. 2011);

• Cognitive complaint verified by objectively confirmed cognitive impairment;

• Alzheimer's disease is a diagnostic considerationExclusion Criteria:

• Head MRI and/or CT within 24 months prior to enrollment;

Exclusion Criteria:

• Normal cognition or subjective complaints that are not verified by cognitive testing.

• Knowledge of amyloid status, in the opinion of the referring dementia expert, may cause significant psychological harm or otherwise negatively impact the patient or family.

• Scan being ordered for nonmedical purposes (e.g., legal, insurance coverage, or employment screening).

• Cancer requiring active therapy (excluding non-melanoma skin cancer);

• Life expectancy less than 24 months based on medical co-morbidities;

• Residence in a skilled nursing facility.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Dementia
• Dementia Frontal
• Mild Cognitive Impairment

Intervention

Device:
• EEG scan
WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings

Locations

Country	Name	City	State
United States	Translational Cognitive Research	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Metabolic Therapy Inc.	Institute of Asian American Adult Development

Country where clinical trial is conducted

United States, 

References & Publications (22)

1. Cassani R, Falk TH, Fraga FJ, Cecchi M, Moore DK, Anghinah R. Towards automated electroencephalography-based Alzheimer's disease diagnosis using portable low-density devices. Biomedical Signal Processing and Control. 2017,33:261-71.

Amenedo E, Díaz F. Ageing-related changes in the processing of attended and unattended standard stimuli. Neuroreport. 1999 Aug 2;10(11):2383-8. — View Citation

Azumi T, Nakashima K, Takahashi K. Aging effects on auditory middle latency responses. Electromyogr Clin Neurophysiol. 1995 Nov;35(7):397-401. — View Citation

Bennys K, Portet F, Touchon J, Rondouin G. Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment. J Clin Neurophysiol. 2007 Oct;24(5):405-12. — View Citation

Boutros NN, Belger A. Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. Biol Psychiatry. 1999 Apr 1;45(7):917-22. — View Citation

Cecchi M, Moore DK, Sadowsky CH, Solomon PR, Doraiswamy PM, Smith CD, Jicha GA, Budson AE, Arnold SE, Fadem KC. A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings. Alzheimers Dement (Amst). 2015 Oct 2;1(4):387-94. doi: 10.1016/j.dadm.2015.08.004. eCollection 2015 Dec. — View Citation

Freire FR, Coelho F, Lacerda JR, da Silva MF, Gonçalves VT, Machado S, Velasques B, Ribeiro P, Basile LFH, Oliveira AMP, Paiva WS, Kanda PAM, Anghinah R. Cognitive rehabilitation following traumatic brain injury. Dement Neuropsychol. 2011 Jan-Mar;5(1):17-25. doi: 10.1590/S1980-57642011DN05010004. Review. — View Citation

Frodl T, Hampel H, Juckel G, Bürger K, Padberg F, Engel RR, Möller HJ, Hegerl U. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology. 2002 Mar;39(2):175-81. — View Citation

Golob EJ, Johnson JK, Starr A. Auditory event-related potentials during target detection are abnormal in mild cognitive impairment. Clin Neurophysiol. 2002 Jan;113(1):151-61. — View Citation

Green DL, Payne L, Polikar R, Moberg PJ, Wolk DA, Kounios J. P50: A candidate ERP biomarker of prodromal Alzheimer's disease. Brain Res. 2015 Oct 22;1624:390-397. doi: 10.1016/j.brainres.2015.07.054. Epub 2015 Aug 6. — View Citation

Hubl D, Kleinlogel H, Frölich L, Weinandi T, Maurer K, Holstein W, Czekalla J, Dierks T. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine. Psychopharmacology (Berl). 2001 Nov;158(3):281-8. — View Citation

Korzyukov O, Pflieger ME, Wagner M, Bowyer SM, Rosburg T, Sundaresan K, Elger CE, Boutros NN. Generators of the intracranial P50 response in auditory sensory gating. Neuroimage. 2007 Apr 1;35(2):814-26. Epub 2006 Dec 19. — View Citation

Kramberger MG, Kåreholt I, Andersson T, Winblad B, Eriksdotter M, Jelic V. Association between EEG abnormalities and CSF biomarkers in a memory clinic cohort. Dement Geriatr Cogn Disord. 2013;36(5-6):319-28. doi: 10.1159/000351677. Epub 2013 Sep 10. — View Citation

Michel CM. Electrical Neuroimaging. Cambridge University Press, Cambridge 2009.

Olichney JM, Yang JC, Taylor J, Kutas M. Cognitive event-related potentials: biomarkers of synaptic dysfunction across the stages of Alzheimer's disease. J Alzheimers Dis. 2011;26 Suppl 3:215-28. doi: 10.3233/JAD-2011-0047. — View Citation

Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Combination of P300 and CSF ß-amyloid(1-42) assays may provide a potential tool in the early diagnosis of Alzheimer's disease. Curr Alzheimer Res. 2010 Jun;7(4):295-9. — View Citation

Polich J, Corey-Bloom J. Alzheimer's disease and P300: review and evaluation of task and modality. Curr Alzheimer Res. 2005 Dec;2(5):515-25. Review. — View Citation

Polich J, Ladish C, Bloom FE. P300 assessment of early Alzheimer's disease. Electroencephalogr Clin Neurophysiol. 1990 May-Jun;77(3):179-89. — View Citation

Pratap-Chand R, Sinniah M, Salem FA. Cognitive evoked potential (P300): a metric for cerebral concussion. Acta Neurol Scand. 1988 Sep;78(3):185-9. — View Citation

Smailovic U, Koenig T, Kåreholt I, Andersson T, Kramberger MG, Winblad B, Jelic V. Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers. Neurobiol Aging. 2018 Mar;63:88-95. doi: 10.1016/j.neurobiolaging.2017.11.005. Epub 2017 Nov 16. — View Citation

Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol Aging. 2010 Feb;31(2):215-23. doi: 10.1016/j.neurobiolaging.2008.03.025. — View Citation

van Dinteren R, Arns M, Jongsma ML, Kessels RP. P300 development across the lifespan: a systematic review and meta-analysis. PLoS One. 2014 Feb 13;9(2):e87347. doi: 10.1371/journal.pone.0087347. eCollection 2014. Review. — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient meeting Appropriate Use Criteria (AUC) with EEG brain scan - P300 and P50 will be measured for correlation between P300 and P50 with amyloid deposition.	Test whether qEEG P300 and P50 waveform amplitudes and auditory response times will lead to correlation with amyloid deposition	10 days